Samsung’s biosimilar etanercept, Brenzys, is listed on the PBS in Australia with “A” flagging enabling substitution at the pharmacy level
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Apr 01, 2017
Samsung’s biosimilar etanercept, Brenzys, is listed on the PBS in Australia with “A” flagging enabling substitution at the pharmacy level
By Bioblast Editor | Mar 28, 2017
Sanofi and Regeneron announced that the FDA has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.
By Bioblast Editor | Mar 24, 2017
Amgen announces during a conference presentation that it has filed an application in EMA for biosimilar trastuzumab ABP 980.
By Bioblast Editor | Mar 23, 2017
Sanofi and Regeneron filed a petition against Immunex, requesting an inter partes review (IPR) of patent 8,679,487. The petitioners argue that the ‘487 patent is invalid on novelty grounds. Earlier this month Sanofi and Regeneron filed a complaint in the District Court of...
By Bioblast Editor | Mar 23, 2017
EMA approves Amgen’s biosimilar adalimumab Amgevita® with a full indication set. This is the first EU approval for biosimilar adalimumab.
By Bioblast Editor | Mar 20, 2017
Sanofi-Aventis, Genzyme Corporation and Regeneron filed a complaint in the District Court of Massachusetts seeking a declaration judgement that its development, manufacturing, sale, promotion and related activities for Dupixent® (dupilumab) do/will not directly or indirectl...
By Bioblast Editor | Mar 14, 2017
Mylan announces global settlement with Genentech & Roche on TmAb with global licenses (excluding Japan, Brazil and Mexico).
By Bioblast Editor | Mar 03, 2017
UK High Court hands down decision in Samsung v Abbvie.
By Bioblast Editor | Mar 02, 2017
PTAB institutes IPR filed by Hospira against Genentech on bevacizumab patents IPR2016-01771 (Patent 7,622,115) and IPR2016-01837 (Patent 7,807,799) from requests filed 9 September 2016.
By Bioblast Editor | Mar 02, 2017
Judge Sleet dismissed Genentech’s suit filed 15 Feb 17 (see below) under Fed Cir’s finding in Amgen v Sandoz.
SUBSCRIBE TO PEARCE IP